Valproic Acid Pharmacodynamics in Epilepsy Treatment
Summary
Valproic acid (VPA) exerts broad-spectrum antiepileptic effects through a combination of synaptic, ionic and epigenetic mechanisms. At therapeutic concentrations, VPA enhances inhibitory γ-aminobutyric acid (GABA) neurotransmission by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase, thereby elevating synaptic GABA levels and prolonging inhibitory postsynaptic currents. Concurrently, the drug stabilises neuronal membranes via blockade of voltage-gated sodium channels and suppression of T-type calcium currents in thalamocortical circuits, reducing neuronal excitability and seizure propagation. Beyond these acute actions, VPA functions as a histone deacetylase (HDAC) inhibitor, modulating gene expression patterns that influence synaptic plasticity, neuronal survival and network remodelling. These multifaceted pharmacodynamic properties underpin VPA’s efficacy across focal and generalised seizure types. However, VPA’s impact on mitochondrial enzymes and on neurogenic niches also contributes to its side-effect profile, notably hepatic toxicity and cognitive adverse effects. Optimisation of dosing regimens, use of sustained-release formulations and exploration of structural analogues aim to maximise antiseizure benefits while mitigating metabolic and neurodevelopmental risks.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Valproic Acid Pharmacodynamics in Epilepsy Treatment publication trend
The graph below shows the total number of articles in valproic acid pharmacodynamics in epilepsy treatment across all publications each year (not limited to Nature Index journals).
Technical terms
Histone deacetylase (HDAC) inhibition: Blockade of enzymes that remove acetyl groups from histone proteins, leading to relaxed chromatin structure and altered gene transcription.
GABA transaminase: A mitochondrial enzyme responsible for the degradation of GABA; inhibition increases GABA availability at inhibitory synapses.
α-Lipoamide dehydrogenase: A mitochondrial flavoprotein that catalyses the reoxidation of dihydrolipoamide in key dehydrogenase complexes; its inhibition disrupts oxidative metabolism.
References
- Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. International Journal of Molecular Sciences (2017).
- Fluvoxamine Ameliorates the Damage to the Neuro-Behavioral Status of Rats Caused by the Administration of Valproic Acid by Preventing Cognitive Memory Deficits and Decreased Hippocampal Cellular Proliferation. Cureus (2024).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.